Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Drugs for Orthopedics/Orthopedic Surgery in Phase II Clinical Development in UNITED STATES

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Heron Therapeutics

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              ESMO 2020 Congress

              Participation Not Confirmed

              Update your events

              Heron Therapeutics Announces Publication of Results From Phase 2b Study of HTX-011 in Patients Undergoing Total Knee Arthroplasty

              Contact the Supplier

              Lead Product(s): Bupivacaine,Meloxicam

              Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: Undisclosed

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 04, 2020

              Details:

              HTX-011 reduced pain and opioid use after primary total knee arthroplasty, The study met all primary and key secondary endpoints, with HTX-011 demonstrating statistically significant reductions in pain intensity following surgery.

              Carmell Therapeutics

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              ESMO 2020 Congress

              Participation Not Confirmed

              Update your events

              FDA grants Carmell Therapeutics Expedited Review for CT-101, Bone Healing Accelerant

              Contact the Supplier

              Lead Product(s): Calcium Phosphate,Blood-derived component

              Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: Undisclosed

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 27, 2020

              Details:

              The Fast Track status offers the company benefits in improving and accelerating the company's trial on Bone Healing Accelerant in open tibia fractures to the target of a Biologic License Application.

              Carmell Therapeutics

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              ESMO 2020 Congress

              Participation Not Confirmed

              Update your events

              Carmell Therapeutics Receives IND Clearance for CT-101, Bone Healing Accelerant

              Contact the Supplier

              Lead Product(s): Calcium Phosphate

              Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: Undisclosed

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 07, 2020

              Details:

              Carmell to begin enrolling in pivotal clinical program for first-of-its-kind Plasma-based Bioactive Material product used in long-bone fractures as an adjunctive treatment.

              PharmaCompass__DigitalAd